Core Viewpoint - Sanara MedTech Inc. is set to present at the Cantor Global Healthcare Conference, highlighting its focus on developing transformative medical technologies aimed at improving clinical outcomes and reducing healthcare costs in surgical and wound care markets [1][2]. Company Overview - Sanara MedTech Inc. specializes in medical technology, particularly in surgical, chronic wound, and skin markets, with a commitment to enhancing clinical outcomes and minimizing healthcare expenditures [3]. - The company markets and distributes a range of products, including CellerateRX Surgical Activated Collagen and FORTIFY TRG Tissue Repair Graft, primarily in the North American advanced wound care and surgical tissue repair markets [3]. - Sanara's product portfolio includes advanced biologic products such as ACTIGEN™ Verified Inductive Bone Matrix and BIASURGE Advanced Surgical Solution, along with wound care products like BIAKŌS Antimicrobial Skin and Wound Cleanser [3]. - The company is actively pursuing long-term strategic partnerships to develop products that improve patient outcomes while reducing overall costs [3]. Upcoming Events - Management will participate in a fireside chat presentation at the Cantor Global Healthcare Conference on September 3, 2025, at approximately 2:45 p.m. Eastern Time [1]. - Presentation materials will be available on the company's investor relations website prior to the event, along with a live audio webcast and an archive for replay after the conference [2].

Core Insights - Sanara MedTech Inc. has launched a pilot program through its subsidiary Tissue Health Plus (THP) aimed at providing value-based wound care solutions for chronic wounds across six states [1][2] - The THP technology platform will serve as a Wound Care Operating System for a provider group, utilizing Co-Pilot software to standardize patient care and streamline administrative processes [2] - The pilot program is expected to validate and optimize the THP technology platform through real-world patient encounters, with plans for expansion to additional practitioners and locations [2] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing technologies to improve clinical outcomes and reduce healthcare costs in surgical and chronic wound markets [4] - The company markets a range of surgical and wound care products primarily in the North American market, including CellerateRX Surgical Activated Collagen and various antimicrobial solutions [4][5] - THP aims to transform the $100+ billion wound care market by addressing gaps in chronic wound care, with a goal of improving healing rates to over 85% and reducing total care costs by more than 25% [3] Technology and Innovation - THP's platform combines AI-powered clinical decision support, virtual care coordination, and an integrated provider network to deliver personalized wound care [3] - The pilot program is part of a broader strategy to engage with payers and financial partners to support the implementation of THP's value-based care solutions [2][3]

Core Viewpoint - Sanara MedTech Inc. is set to report its first quarter 2025 financial results on May 14, 2025, before U.S. markets open, indicating ongoing developments in its financial performance and business strategy [1]. Group 1: Financial Reporting - The company will host a conference call and webcast on May 14, 2025, at 8:00 a.m. Eastern Time to discuss the financial results for the quarter ended March 31, 2025, followed by a Q&A session [2]. - A telephonic replay of the conference call will be available until May 28, 2025, providing access to the discussion for those unable to attend live [2]. Group 2: Company Overview - Sanara MedTech Inc. focuses on developing and commercializing transformative technologies aimed at improving clinical outcomes and reducing healthcare costs in surgical, chronic wound, and skincare markets [4]. - The company markets and distributes a range of surgical, wound, and skincare products primarily in the North American advanced wound care and surgical tissue repair markets [4]. - Key products include CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft, and various advanced biologic products, indicating a diverse product portfolio [4]. - The company is actively seeking long-term strategic partnerships to enhance product offerings that improve outcomes at a lower overall cost [4].